Real pricing only appears after a face scan, an ID upload, and biometric consent have already been submitted to the clinic
Based on the current clinical trial timeline, retatrutide Phase 3 trial results are expected to be published in late 2026 or 2027
These obese patients show an association with a non-eosinophilic phenotype that is characterized by late-onset asthma in middle-aged females with high expression of symptoms [12] and who may have some resistance to current therapeutics, including steroid resistance [13], tend to have poorer asthma control and higher risk of exacerbation [14]
GLP-1RAs showed significantly more reduction of cardiovascular endpoints than other second- or third-line glucose-lowering medications
44 Pyroptosis has been reported as a significant mechanism of cell death in APAP-induced liver injury, involving activation of the NLRP3 inflammasome and subsequent caspase-1 activation
The most common side effects are redness and swelling after treatment for rosacea or cherry angiomas